Tablets and medicine bottle

Delivering the correct dosages of warfarin

In partnership with local NHS Trusts through Liverpool Health Partners we have undertaken significant research on warfarin, the main oral anticoagulant in the UK.

This research has shown that personalising the dose to the patient, based on their genes, age and body weight, can help set the right dose and reduce both risk and the time it takes for the medicine to become effective.

The problem has been that the level of anticoagulation in response to a fixed-dose routine of warfarin is difficult to predict during the initiation of therapy. However, comparing the effect of genotype-guided dosing with that of standard dosing on anticoagulation control showed that the mean percentage of time in the therapeutic range was 67.4% in the genotype-guided group as compared with 60.3% in the control group, with significantly fewer incidences of excessive anticoagulation in the genotype-guided group.

P‌rofessor Sir Munir Pirmohamed carried out this research as part of his work in Pharmacogenetics in the Department of Molecular and Clinical Pharmacology.